Literature DB >> 24652965

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Holbrook E Kohrt1, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E M Herman, Jonathon P Butchar, Carolyn Cheney, Xiaoli Zhang, Joseph J Buggy, Natarajan Muthusamy, Ronald Levy, Amy J Johnson, John C Byrd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24652965      PMCID： PMC3962169          DOI： 10.1182/blood-2014-01-547869

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

2.  CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Roch Houot; Matthew J Goldstein; Kipp Weiskopf; Ash A Alizadeh; Josh Brody; Antonia Müller; Russell Pachynski; Debra Czerwinski; Steven Coutre; Mark P Chao; Lieping Chen; Thomas F Tedder; Ronald Levy
Journal:  Blood       Date:  2010-12-30       Impact factor: 22.113

3.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Authors:  Julie A Di Paolo; Tao Huang; Mercedesz Balazs; James Barbosa; Kai H Barck; Brandon J Bravo; Richard A D Carano; James Darrow; Douglas R Davies; Laura E DeForge; Lauri Diehl; Ronald Ferrando; Steven L Gallion; Anthony M Giannetti; Peter Gribling; Vincent Hurez; Sarah G Hymowitz; Randall Jones; Jeffrey E Kropf; Wyne P Lee; Patricia M Maciejewski; Scott A Mitchell; Hong Rong; Bart L Staker; J Andrew Whitney; Sherry Yeh; Wendy B Young; Christine Yu; Juan Zhang; Karin Reif; Kevin S Currie
Journal:  Nat Chem Biol       Date:  2010-11-28       Impact factor: 15.040

4.  Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.

Authors:  Dianne Khurana; Laura N Arneson; Renee A Schoon; Christopher J Dick; Paul J Leibson
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 5.  From the bench to the bedside: ways to improve rituximab efficacy.

Authors:  Guillaume Cartron; Hervé Watier; Josée Golay; Philippe Solal-Celigny
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

6.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  6 in total
  86 in total

Review 1.  Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Authors:  Amin Aalipour; Ranjana H Advani
Journal:  Ther Adv Hematol       Date:  2014-08

Review 2.  Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Authors:  Deborah M Stephens; Stephen E Spurgeon
Journal:  Ther Adv Hematol       Date:  2015-10

3.  Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Authors:  Li Ren; Amanda Campbell; Huiqing Fang; Shalini Gautam; Saranya Elavazhagan; Kavin Fatehchand; Payal Mehta; Andrew Stiff; Brenda F Reader; Xiaokui Mo; John C Byrd; William E Carson; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

Review 4.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

Review 5.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

6.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Authors:  Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien
Journal:  Lancet Oncol       Date:  2014-08-20       Impact factor: 41.316

Review 7.  Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).

Authors:  Erin M Pettijohn; Shuo Ma
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

8.  Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.

Authors:  Minh Ngoc Duong; Eva-Laure Matera; Doriane Mathé; Anne Evesque; Sandrine Valsesia-Wittmann; Béatrice Clémenceau; Charles Dumontet
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 9.  Targeted therapies in CLL: mechanisms of resistance and strategies for management.

Authors:  Jennifer A Woyach; Amy J Johnson
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

10.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.